tiprankstipranks
Advertisement
Advertisement

PTHS Stock Latest News

Pelthos Highlights Infectious Disease Portfolio at Investor Meetings
Company AnnouncementsPelthos Highlights Infectious Disease Portfolio at Investor Meetings
1d ago
8K
PTHS
Pelthos Therapeutics Appoints John M. Gay as CFO
PremiumCompany Announcements
Pelthos Therapeutics Appoints John M. Gay as CFO
5d ago
8K
PTHS
Pelthos Therapeutics says John Gay to succeed Francis Knuettel II as CFO
PremiumThe Fly
Pelthos Therapeutics says John Gay to succeed Francis Knuettel II as CFO
5d ago
PTHS
Pelthos Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Pelthos Therapeutics initiated with an Overweight at Cantor Fitzgerald
14d ago
PTHS
Pelthos Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Pelthos Therapeutics initiated with an Overweight at Cantor Fitzgerald
14d ago
PTHS
Pelthos Therapeutics doses first patient in CT2000 trial
PremiumThe FlyPelthos Therapeutics doses first patient in CT2000 trial
15d ago
PTHS
Pelthos Therapeutics Inc trading resumes
Premium
The Fly
Pelthos Therapeutics Inc trading resumes
23d ago
PTHS
Pelthos Therapeutics Inc trading halted, volatility trading pause
Premium
The Fly
Pelthos Therapeutics Inc trading halted, volatility trading pause
23d ago
PTHS
Pelthos Therapeutics price target raised to $62 from $60 at Oppenheimer
PremiumThe Fly
Pelthos Therapeutics price target raised to $62 from $60 at Oppenheimer
26d ago
PTHS
Pelthos Highlights 2025 Results and Portfolio Expansion Progress
PremiumCompany Announcements
Pelthos Highlights 2025 Results and Portfolio Expansion Progress
27d ago
8K
PTHS
Pelthos Therapeutics reports Q4 EPS ($6.87) vs. ($3.19) last year
PremiumThe Fly
Pelthos Therapeutics reports Q4 EPS ($6.87) vs. ($3.19) last year
27d ago
PTHS
PTHS Earnings this Week: How Will it Perform?
PremiumPre-Earnings
PTHS Earnings this Week: How Will it Perform?
29d ago
PTHS
Pelthos Therapeutics initiated with an Overweight at Piper Sandler
PremiumThe FlyPelthos Therapeutics initiated with an Overweight at Piper Sandler
2M ago
PTHS
Pelthos Therapeutics price target lowered to $55 from $57 at Roth Capital
Premium
The Fly
Pelthos Therapeutics price target lowered to $55 from $57 at Roth Capital
2M ago
PTHS
Pelthos Therapeutics files $200M mixed securities shelf
Premium
The Fly
Pelthos Therapeutics files $200M mixed securities shelf
2M ago
PTHS
Pelthos Therapeutics price target raised to $60 from $57 at Oppenheimer
PremiumThe Fly
Pelthos Therapeutics price target raised to $60 from $57 at Oppenheimer
3M ago
PTHS
Horizon Technology provides $50M loan facility to Pelthos Therapeutics
PremiumThe Fly
Horizon Technology provides $50M loan facility to Pelthos Therapeutics
3M ago
HRZN
PTHS
Pelthos Therapeutics Secures $50 Million Venture Loan Financing
PremiumCompany Announcements
Pelthos Therapeutics Secures $50 Million Venture Loan Financing
3M ago
8K
PTHS
Pelthos Therapeutics secures up to $50M senior secured term loan
PremiumThe Fly
Pelthos Therapeutics secures up to $50M senior secured term loan
3M ago
HRZN
PTHS
Pelthos Therapeutics Details Q1 2026 Growth Strategy
PremiumCompany AnnouncementsPelthos Therapeutics Details Q1 2026 Growth Strategy
3M ago
8K
PTHS
Pelthos Therapeutics: Xeglyze Acquisition and Dermatology Portfolio Drive Multi‑Year Upside and Support Buy Rating
Premium
Ratings
Pelthos Therapeutics: Xeglyze Acquisition and Dermatology Portfolio Drive Multi‑Year Upside and Support Buy Rating
3M ago
PTHS
Pelthos Therapeutics acquires Xeglyze topical treatment for $1.8M
Premium
The Fly
Pelthos Therapeutics acquires Xeglyze topical treatment for $1.8M
3M ago
PTHS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >